PPARs and mitochondrial metabolism: From NAFLD to HCC

PPAR Research

Volumn 2016, Issue , 2016, Pages

  Mello, Tommaso ^a   Materozzi, Maria ^a   Galli, Andrea ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

CIRCADIAN RHYTHM; HUMAN; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER MITOCHONDRION; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; REVIEW;

EID: 85009476006     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2016/7403230     Document Type: Review

References (212)

1. J. Ferlay, I. Soerjomataram, M. Ervik, et al., GLOBOCAN 2012 v1.0, Cancer Incidence and MortalityWorldwide, IARC Cancer-Base no. 11, International Agency for Research on Cancer, 2013, http://globocan.iarc.fr.
2. H. B. El-Serag, "Hepatocellular carcinoma, " New England Journal of Medicine, vol. 365, no. 12, pp. 1118-1127, 2011.
3. Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, "Global epidemiology of nonalcoholic fatty liver disease-meta-Analytic assessment of prevalence, incidence, and outcomes, " Hepatology, vol. 64, no. 1, pp. 73-84, 2016.
4. B. Q. Starley, C. J. Calcagno, and S. A. Harrison, "Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, " Hepatology, vol. 51, no. 5, pp. 1820-1832, 2010.
5. H. B. El-Serag, T. Tran, and J. E. Everhart, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma, " Gastroenterology, vol. 126, no. 2, pp. 460-468, 2004.
6. N. Chalasani, Z. Younossi, J. E. Lavine, et al., "The diagnosis and management of non-Alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, AmericanCollege of Gastroenterology, and the American GastroenterologicalAssociation, " Hepatology, vol. 55, no. 6, pp. 2005-2023, 2012.
7. M. Masarone, A. Federico, L. Abenavoli, C. Loguercio, and M. Persico, "Non alcoholic fatty liver: epidemiology and natural history, " Reviews on Recent Clinical Trials, vol. 9, no. 3, pp. 126-133, 2014.
8. N. Kawada, K. Imanaka, T. Kawaguchi, et al., "Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis, " Journal of Gastroenterology, vol. 44, no. 12, pp. 1190-1194, 2009.
9. O. Warburg, "On the origin of cancer cells, " Science, vol. 123, no. 3191, pp. 309-314, 1956.
10. O. warburg, "On respiratory impairment in cancer cells, " Science, vol. 124, no. 3215, pp. 269-270, 1956.
11. C. S. Ahn and C. M. Metallo, "Mitochondria as biosynthetic factories for cancer proliferation, " Cancer & Metabolism, vol. 3, no. 1, article 1, 2015.
12. A. W. F. Janssen, B. Betzel, G. Stoopen, et al., "The impact of PPAR- Activation on whole genome gene expression in human precision cut liver slices, " BMC Genomics, vol. 16, no. 1, article 760, 2015.
13. M. Rakhshandehroo, G. Hooiveld, M. Müller, and S. Kersten, "Comparative analysis of gene regulation by the transcription factor PPAR- between mouse and human, " PLoS ONE, vol. 4, no. 8, Article ID e6796, 2009.
14. W. Wahli and L. Michalik, "PPARs at the crossroads of lipid signaling and inflammation, " Trends in Endocrinology and Metabolism, vol. 23, no. 7, pp. 351-363, 2012.
15. M. V. Chakravarthy, Z. Pan, Y. Zhu, et al., "'New' hepatic fat activates PPAR- To maintain glucose, lipid, and cholesterol homeostasis, " Cell Metabolism, vol. 1, no. 5, pp. 309-322, 2005.
16. D. Patsouris, J. K. Reddy, M. Müller, and S. Kersten, "Peroxisome proliferator-Activated receptor - mediates the effects of high-fat diet on hepatic gene expression, " Endocrinology, vol. 147, no. 3, pp. 1508-1516, 2006.
17. P. G. P. Martin, H. Guillou, F. Lasserre, et al., "Novel aspects of PPAR-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study, " Hepatology, vol. 45, no. 3, pp. 767-777, 2007.
18. L. M. Sanderson, P. J. de Groot, G. J. E. J. Hooiveld, et al., "Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics, " PLoS ONE, vol. 3, no. 2, Article ID e1681, 2008.
19. S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli, "Peroxisome proliferator-Activated receptor -mediates the adaptive response to fasting, " Journal of Clinical Investigation, vol. 103, no. 11, pp. 1489-1498, 1999.
20. A. Montagner, A. Polizzi, E. Fouche, et al., "Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD, " Gut, vol. 65, no. 7, pp. 1202-1214, 2016.
21. M. V. Chakravarthy, I. J. Lodhi, L. Yin, et al., "Identification of a Physiologically Relevant Endogenous Ligand for PPAR- in Liver, " Cell, vol. 138, no. 3, pp. 476-488, 2009.
22. T. Yamauchi, J. Kamon, Y. Ito, et al., "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, " Nature, vol. 423, no. 6941, pp. 762-769, 2003.
23. P. Iglesias, R. Selgas, S. Romero, and J. J. Díez, "Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21, " European Journal of Endocrinology, vol. 167, no. 3, pp. 301-309, 2012.
24. F. M. Fisher, P. C. Chui, I. A. Nasser, et al., "Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets, " Gastroenterology, vol. 147, no. 5, pp. 1073.e6-1083.e6, 2014.
25. E. Szalowska, H. A. Tesfay, S. A. van Hijum, and S. Kersten, "Transcriptomic signatures of peroxisome proliferatoractivated receptor - (PPAR-) in different mouse liver models identify novel aspects of its biology, " BMC Genomics, vol. 15, no. 1, article 1106, 2014.
26. S. Kersten, M. Rakhshandehroo, B. Knoch, and M. Müller, "Peroxisome proliferator-Activated receptor alpha target genes, " PPAR Research, Article ID612089, 2010.
27. D. G. Cotter, B. Ercal, X. Huang, et al., "Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia, " The Journal of Clinical Investigation, vol. 124, no. 12, pp. 5175-5190, 2014.
28. Y. Wang, A.-W. Mohsen, S. J. Mihalik, E. S. Goetzman, and J. Vockley, "Evidence for physical association of mitochondrial fatty acid oxidation and oxidative phosphorylation complexes, " Journal of Biological Chemistry, vol. 285, no. 39, pp. 29834-29841, 2010.
29. F. Villarroya, R. Iglesias, and M. Giralt, "PPARs in the control of uncoupling proteins gene expression, " PPAR Research, vol. 2007, Article ID 74364, 12 pages, 2007.
30. L. J. Kelly, P. P. Vicario, G. M. Thompson, et al., "Peroxisome proliferator-Activated receptors and - mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression, " Endocrinology, vol. 139, no. 12, pp. 4920-4927, 1998.
31. G. Y. Lee, N. H. Kim, Z.-S. Zhao, B. S. Cha, and Y. S. Kim, "Peroxisomal-proliferator-Activated receptor - Activates transcription of the rat hepaticmalonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level, " Biochemical Journal, vol. 378, no. 3, pp. 983-990, 2004.
32. L. Cheng, G. Ding, Q. Qin, et al., "Cardiomyocyte-restricted peroxisome proliferator-Activated receptor- deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy, " Nature Medicine, vol. 10, no. 11, pp. 1245-1250, 2004.
33. D. M. Muoio, P. S. MacLean, D. B. Lang, et al., "Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-Activated receptor (PPAR)- knock-out mice. Evidence for compensatory regulation by PPAR, " Journal of Biological Chemistry, vol. 277, no. 29, pp. 26089-26097, 2002.
34. U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E. O. Muscat, "The peroxisome proliferator-Activated receptor /-Agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells, " Molecular Endocrinology, vol. 17, no. 12, pp. 2477-2493, 2003.
35. B. Brunmair, K. Staniek, J. Dörig, et al., "Activation of PPARdelta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids, " Diabetologia, vol. 49, no. 11, pp. 2713-2722, 2006.
36. L. Jiang, J. Wan, L.-Q. Ke, Q.-G. Lü, and N.-W. Tong, "Activation of PPAR promotes mitochondrial energy metabolism and decreases basal insulin secretion in palmitate-Treated -cells, " Molecular and Cellular Biochemistry, vol. 343, no. 1-2, pp. 249-256, 2010.
37. M. C. Manio, K. Inoue, M. Fujitani, S. Matsumura, and T. Fushiki, "Combined pharmacological activation of AMPK and PPAR potentiates the effects of exercise in trained mice, " Physiological Reports, vol. 4, no. 5, Article ID e12625, 2016.
38. S. Liu, B. Hatano, M. Zhao, et al., "Role of peroxisome proliferator-Activated receptor / in hepatic metabolic regulation, " Journal of Biological Chemistry, vol. 286, no. 2, pp. 1237-1247, 2011.
39. L. M. Sanderson, M. V. Boekschoten, B. Desvergne, M. Müller, and S. Kersten, "Transcriptional profiling reveals divergent roles of PPAR- And PPAR/ in regulation of gene expression in mouse liver, " Physiological Genomics, vol. 41, no. 1, pp. 42-52, 2010.
40. S. Liu, J. D. Brown, K. J. Stanya, et al., "A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use, " Nature, vol. 502, no. 7472, pp. 550-554, 2013.
41. D.-Y. Zhu, J.-Y. Wu, H. Li, et al., "PPAR- facilitatingmaturation of hepatic-like tissue derived from mouse embryonic stem cells accompanied bymitochondriogenesis andmembrane potential retention, " Journal of Cellular Biochemistry, vol. 109, no. 3, pp. 498-508, 2010.
42. E. Hondares, M. Rosell, J. Díaz-Delfín, et al., "Peroxisome proliferator-Activated receptor - (PPAR-) induces PPAR coactivator 1- (PGC-1-) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16, " Journal of Biological Chemistry, vol. 286, no. 50, pp.43112-43122, 2011.
43. M. Schuler, F. Ali, C. Chambon, et al., "PGC1- expression is controlled in skeletal muscles by PPAR, whose ablation results in fiber-Type switching, obesity, and type 2 diabetes, " Cell Metabolism, vol. 4, no. 5, pp. 407-414, 2006.
44. E. Hondares, I. Pineda-Torra, R. Iglesias, B. Staels, F. Villarroya, and M. Giralt, "PPAR, but not PPAR-, activates PGC-1- gene transcription in muscle, " Biochemical and Biophysical Research Communications, vol. 354, no. 4, pp. 1021-1027, 2007.
45. S. Herzig, F. Long, U. S. Jhala, et al., "CREB regulates hepatic gluconeogenesis through the coactivator PGC-1, " Nature, vol. 413, no. 6852, pp. 179-183, 2001.
46. M. T. Nakamura, B. E. Yudell, and J. J. Loor, "Regulation of energy metabolism by long-chain fatty acids, " Progress in Lipid Research, vol. 53, no. 1, pp. 124-144, 2014.
47. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-Activated receptor- is a negative regulator of macrophage activation, " Nature, vol. 391, no. 6662, pp. 79-82, 1998.
48. R. E. Soccio, E. R. Chen, and M. A. Lazar, "Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes, " Cell Metabolism, vol. 20, no. 4, pp. 573-591, 2014.
49. M. Ahmadian, J. M. Suh, N. Hah, et al., "PPAR signaling and metabolism: the good, the bad and the future, " Nature Medicine, vol. 19, no. 5, pp. 557-566, 2013.
50. O. Gavrilova, M. Haluzik, K. Matsusue, et al., "Liver peroxisome proliferator-Activated receptor contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass, " Journal of Biological Chemistry, vol. 278, no. 36, pp. 34268-34276, 2003.
51. K. Matsusue, M. Haluzik, G. Lambert, et al., "Liver-specific disruption of PPAR in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes, "The Journal of Clinical Investigation, vol. 111, no. 5, pp. 737-747, 2003.
52. P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, "A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis, " Cell, vol. 92, no. 6, pp. 829-839, 1998.
53. J. St-Pierre, J. Lin, S. Krauss, et al., "Bioenergetic analysis of peroxisome proliferator-Activated receptor coactivators 1- And 1 (PGC-1- And PGC-1) in muscle cells, " The Journal of Biological Chemistry, vol. 278, no. 29, pp. 26597-26603, 2003.
54. W. Fan and R. Evans, "PPARs and ERRs: molecular mediators of mitochondrial metabolism, " Current Opinion in Cell Biology, vol. 33, pp. 49-54, 2015.
55. E. Hondares, O. Mora, P. Yubero, et al., "Thiazolidinediones and rexinoids induce peroxisome proliferator-Activated receptorcoactivator (PGC)-1- gene transcription: an autoregulatory loop controls PGC-1- expression in adipocytes via peroxisome proliferator-Activated receptor- coactivation, " Endocrinology, vol. 147, no. 6, pp. 2829-2838, 2006.
56. H. Maruyama, S. Kiyono, T. Kondo, T. Sekimoto, and O. Yokosuka, "Palmitate-induced regulation of PPAR via PGC1-: amechanism for lipid accumulation in the liver in nonalcoholic fatty liver disease, " International Journal ofMedical Sciences, vol. 13, no. 3, pp. 169-178, 2016.
57. P. D. Ray, B.-W. Huang, and Y. Tsuji, "Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling, " Cellular Signalling, vol. 24, no. 5, pp. 981-990, 2012.
58. M. Schieber and N. S. Chandel, "ROS function in redox signaling and oxidative stress, " Current Biology, vol. 24, no. 10, pp. R453-R462, 2014.
59. L. Zeng, W. J. Tang, J. J. Yin, and B. J. Zhou, "Signal transductions and nonalcoholic fatty liver: a mini-review, " International Journal of Clinical and Experimental Medicine, vol. 7, no. 7, pp. 1624-1631, 2014.
60. I. Afanas'ev, "Signaling of reactive oxygen and nitrogen species in diabetes mellitus, " OxidativeMedicine and Cellular Longevity, vol. 3, no. 6, pp. 361-373, 2010.
61. I. Afanas'ev, "Reactive oxygen species signaling in cancer: comparison with aging, " Aging and Disease, vol. 2, no. 3, pp. 219-230, 2011.
62. J. St-Pierre, J. A. Buckingham, S. J. Roebuck, and M. D. Brand, "Topology of superoxide production from different sites in the mitochondrial electron transport chain, " The Journal of Biological Chemistry, vol. 277, no. 47, pp. 44784-44790, 2002.
63. E. B. Tahara, F. D. T. Navarete, and A. J. Kowaltowski, "Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation, " Free Radical Biology and Medicine, vol. 46, no. 9, pp. 1283-1297, 2009.
64. T. Mello, F. Zanieri, E. Ceni, and A. Galli, "Oxidative stress in the healthy and wounded hepatocyte: a cellular organelles perspective, " Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 8327410, 15 pages, 2016.
65. C. Ricci, V. Pastukh, J. Leonard, et al., "Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis, "American Journal of Physiology-Cell Physiology, vol. 294, no. 2, pp. C413-C422, 2008.
66. H. Kawahara, M. Fukura, M. Tsuchishima, and S. Takase, "Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis, " Alcoholism: Clinical and Experimental Research, vol. 31, supplement 1, pp. S54-S60, 2007.
67. L. Llacuna, A. Fernández, C. V. Montfort, et al., "Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury, " Journal of Hepatology, vol. 54, no. 5, pp. 1002-1010, 2011.
68. L. A. Videla, R. Rodrigo, M. Orellana, et al., "Oxidative stressrelated parameters in the liver of non-Alcoholic fatty liver disease patients, " Clinical Science, vol. 106, no. 3, pp. 261-268, 2004.
69. J. Xiao and G. L. Tipoe, "Inflammasomes in non-Alcoholic fatty liver disease, " Frontiers in Bioscience, vol. 21, pp. 683-695, 2016.
70. D. Sharma and T. Kanneganti, "The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation, " The Journal of Cell Biology, vol. 213, no. 6, pp. 617-629, 2016.
71. M. Y. Lee, R. Choi, H. M. Kim, et al., "Peroxisome proliferatoractivated receptor delta agonist attenuates hepatic steatosis by anti-inflammatory mechanism, " Experimental & Molecular Medicine, vol. 44, no. 10, pp. 578-585, 2012.
72. S. Seki, T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, and K. Wakasa, "In situ detection of lipid peroxidation and oxidative DNA damage in non-Alcoholic fatty liver diseases, " Journal of Hepatology, vol. 37, no. 1, pp. 56-62, 2002.
73. S. H. Caldwell, R. H. Swerdlow, E. M. Khan, et al., "Mitochondrial abnormalities in non-Alcoholic steatohepatitis, " Journal of Hepatology, vol. 31, no. 3, pp. 430-434, 1999.
74. M. Pérez-Carreras, P. Del Hoyo, M. A. Martín, et al., "Defective hepaticmitochondrial respiratory chain in patients with nonalcoholic steatohepatitis, " Hepatology, vol. 38, no. 4, pp. 999-1007, 2003.
75. R. Gambino, G. Musso, and M. Cassader, "Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities, " Antioxidants and Redox Signaling, vol. 15, no. 5, pp. 1325-1365, 2011.
76. Y. Ikura, M. Ohsawa, T. Suekane, et al., "Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression, " Hepatology, vol. 43, no. 3, pp. 506-514, 2006.
77. S. Li, X.-Y. Zeng, X. Zhou, et al., "Dietary cholesterol induces hepatic inflammation and bluntsmitochondrial function in the liver of high-fat-fed mice, " Journal of Nutritional Biochemistry, vol. 27, pp. 96-103, 2016.
78. V. Ribas, C. García-Ruiz, and J. C. Fernández-Checa, "Mitochondria, cholesterol and cancer cell metabolism, " Clinical and Translational Medicine, vol. 5, article 22, 2016.
79. E. Ip, G. C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq, "Central role of PPAR-dependent hepatic lipid turnover in dietary steatohepatitis in mice, " Hepatology, vol. 38, no. 1, pp. 123-132, 2003.
80. E. Ip, G. Farrell, P. Hall, G. Robertson, and I. Leclercq, "Administration of the potent PPAR- Agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice, " Hepatology, vol. 39, no. 5, pp. 1286-1296, 2004.
81. P. Costet, C. Legendre, J. Moré, A. Edgar, P. Galtier, and T. Pineau, "Peroxisome proliferator-Activated receptor -isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis, " The Journal of Biological Chemistry, vol. 273, no. 45, pp. 29577-29585, 1998.
82. M. A. Abdelmegeed, S.-H. Yoo, L. E. Henderson, F. J. Gonzalez, K. J. Woodcroft, and B.-J. Song, "PPAR- expression protects male mice from high fat-induced nonalcoholic fatty liver, " The Journal of Nutrition, vol. 141, no. 4, pp. 603-610, 2011.
83. K. Begriche, J. Massart, M.-A. Robin, F. Bonnet, and B. Fromenty, "Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease, " Hepatology, vol. 58, no. 4, pp. 1497-1507, 2013.
84. M. Monetti, M. C. Levin, M. J. Watt, et al., "Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGATin the liver, " CellMetabolism, vol. 6, no. 1, pp. 69-78, 2007.
85. W. Liao, T. Y. Hui, S. G. Young, and R. A. Davis, "Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER, " Journal of Lipid Research, vol. 44, no. 5, pp. 978-985, 2003.
86. Z. Z. Li, M. Berk, T. M. McIntyre, and A. E. Feldstein, "Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-Coa desaturase, " Journal of Biological Chemistry, vol. 284, no. 9, pp. 5637-5644, 2009.
87. M. Sharma, S. Mitnala, R. K. Vishnubhotla, R. Mukherjee, D. N. Reddy, and P. N. Rao, "The riddle of nonalcoholic fatty liver disease: progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis, " Journal of Clinical and Experimental Hepatology, vol. 5, no. 2, pp. 147-158, 2015.
88. K. Beier, A. Völkl, and D. Fahimi, "TNF- downregulates the peroxisome proliferator activated receptor- And the mRNAs encoding peroxisomal proteins in rat liver, " FEBS Letters, vol. 412, no. 2, pp. 385-387, 1997.
89. V. G. Giby and T. A. Ajith, "Role of adipokines and peroxisome proliferator-Activated receptors in nonalcoholic fatty liver disease, " World Journal of Hepatology, vol. 6, no. 8, pp. 570-579, 2014.
90. S. R. Ande, K. H. Nguyen, B. L. Grégoire Nyomba, and S. Mishra, "Prohibitin-induced, obesity-Associated insulin resistance and accompanying low-grade inflammation causesNASH and HCC, " Scientific Reports, vol. 6, Article ID23608, 2016.
91. S. Francque, A. Verrijken, S. Caron, et al., "PPAR- gene expression correlates with severity and histological treatment response in patients with non-Alcoholic steatohepatitis, " Journal of Hepatology, vol. 63, no. 1, pp. 164-173, 2015.
92. Y. M. Shah, K. Morimura, Q. Yang, T. Tanabe, M. Takagi, and F. J. Gonzalez, "Peroxisome proliferator-Activated receptor -regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation, "Molecular and Cellular Biology, vol. 27, no. 12, pp. 4238-4247, 2007.
93. N. Tanaka, K. Moriya, K. Kiyosawa, K. Koike, F. J. Gonzalez, and T. Aoyama, "PPAR- Activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice, "The Journal of Clinical Investigation, vol. 118, no. 2, pp. 683-694, 2008.
94. F. J. Gonzalez and Y. M. Shah, "PPAR-: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators, " Toxicology, vol. 246, no. 1, pp. 2-8, 2008.
95. S. Bonovas, G. K. Nikolopoulos, and P. G. Bagos, "Use of fibrates and cancer risk: a systematic review and meta-Analysis of 17 long-Term randomized placebo-controlled trials, " PLoS ONE, vol. 7, no. 9, Article ID 0045259, 2012.
96. N. Zhang, E. S. H. Chu, J. Zhang, et al., "Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-B signaling pathway, " Oncotarget, vol. 5, no. 18, pp. 8330-8340, 2014.
97. M. C. Sugden and M. J. Holness, "Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases, " Archives of Physiology and Biochemistry, vol. 112, no. 3, pp. 139-149, 2006.
98. M. Grabacka, M. Pierzchalska, and K. Reiss, "Peroxisome proliferator activated receptor - ligands as anticancer drugs targeting mitochondrial metabolism, " Current Pharmaceutical Biotechnology, vol. 14, no. 3, pp. 342-356, 2013.
99. S. Oka, R. Alcendor, P. Zhai, et al., "PPAR-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway, " CellMetabolism, vol. 14, no. 5, pp. 598-611, 2011.
100. M. Pawlak, E. Baugé, W. Bourguet, et al., "The transrepressive activity of peroxisome proliferator-Activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice, " Hepatology, vol. 60, no. 5, pp. 1593-1606, 2014.
101. S. Kamarajugadda, J. R. Becker, E. A. Hanse, et al., "Cyclin D1 represses peroxisome proliferator-Activated receptor alpha and inhibits fatty acid oxidation, " Oncotarget, vol. 7, no. 30, pp. 47674-47686, 2016.
102. X. Qin, X. Xie, Y. Fan, et al., "Peroxisome proliferator-Activated receptor- induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice, " Hepatology, vol. 48, no. 2, pp. 432-441, 2008.
103. M. Goudarzi, T. Koga, C. Khozoie, et al., "PPAR/ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity, " Toxicology, vol. 311, no. 3, pp. 87-98, 2013.
104. C.-H. Lee, P. Olson, A. Hevener, et al., "PPAR regulates glucose metabolism and insulin sensitivity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444-3449, 2006.
105. M. Zarei, E. Barroso, R. Leiva, et al., "Heme-regulated eIF2-kinase modulates hepatic FGF21 and is activated by PPAR/-deficiency, " Diabetes, vol. 65, no. 10, pp. 3185-3199, 2016.
106. Y. Zhang, T. Lei, J. F. Huang, et al., "The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes, " Molecular and Cellular Endocrinology, vol. 342, no. 1-2, pp. 41-47, 2011.
107. J. Xu, D. J. Lloyd, C. Hale, et al., "Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice, " Diabetes, vol. 58, no. 1, pp. 250-259, 2009.
108. L. Serrano-Marco, R. Rodríguez-Calvo, I. El Kochairi, et al., "Activation of peroxisome proliferator-Activated receptor-/- (PPAR-/-) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes, " Diabetes, vol. 60, no. 7, pp. 1990-1999, 2011.
109. X. Li, J. Li, X. Lu, et al., "Treatment withPPAR agonist alleviates non-Alcoholic fatty liver disease bymodulating glucose and fatty acidmetabolic enzymes in a ratmodel, " International Journal of Molecular Medicine, vol. 36, no. 3, pp. 767-775, 2015.
110. H. J. Lee, J. E. Yeon, E. J. Ko, et al., "Peroxisome proliferatoractivated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease, " World Journal of Gastroenterology, vol. 21, no. 45, pp. 12787-12799, 2015.
111. L. A. Bojic, D. E. Telford, M. D. Fullerton, et al., "PPAR activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity, " Journal of Lipid Research, vol. 55, no. 7, pp. 1254-1266, 2014.
112. U. Risérus, D. Sprecher, T. Johnson, et al., "Activation of peroxisome proliferator-Activated receptor (PPAR) promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men, " Diabetes, vol. 57, no. 2, pp. 332-339, 2008.
113. H. E. Bays, S. Schwartz, T. Littlejohn III, et al., "MBX-8025, a novel peroxisome proliferator receptor- Agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin, " Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 9, pp. 2889-2897, 2011.
114. H.-X. Liu, Y. Fang, Y. Hu, F. J. Gonzalez, J. Fang, and Y.-J. Y. Wan, "PPAR regulates liver regeneration by modulating Akt and E2f signaling, " PLoS ONE, vol. 8, no. 6, Article ID e65644, 2013.
115. M. Vacca, S. D'Amore, G. Graziano, et al., "Clustering nuclear receptors in liver regeneration identifies candidate modulators of hepatocyte proliferation and hepatocarcinoma, " PLoS ONE, vol. 9, no. 8, Article ID e104449, 2014.
116. H. E. Hollingshead, R. L. Killins, M. G. Borland, et al., "Peroxisome proliferator-Activated receptor-/ (PPAR/) ligands do not potentiate growth of human cancer cell lines, " Carcinogenesis, vol. 28, no. 12, pp. 2641-2649, 2007.
117. L. Xu, C. Han, K. Lim, and T. Wu, "Cross-Talk between peroxisome proliferator-Activated receptor and cytosolic phospholipase A2-/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells, " Cancer Research, vol. 66, no. 24, pp. 11859-11868, 2006.
118. S. Handeli and J. A. Simon, "A small-molecule inhibitor of Tcf/-catenin signaling down-regulates PPAR and PPAR-Activities, " Molecular CancerTherapeutics, vol. 7, no. 3, pp. 521-529, 2008.
119. C. Y. Cao, S. W.-F. Mok, V. W.-S. Cheng, and S. K.-W. Tsui, "The FHL2 regulation in the transcriptional circuitry of human cancers, " Gene, vol. 572, no. 1, pp. 1-7, 2015.
120. C.-F. Ng, P. K.-S. Ng, V. W.-Y. Lui, et al., "FHL2 exhibits antiproliferative and anti-Apoptotic activities in liver cancer cells, " Cancer Letters, vol. 304, no. 2, pp. 97-106, 2011.
121. H. Yau, K. Rivera, R. Lomonaco, and K. Cusi, "The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus, " Current Diabetes Reports, vol. 13, no. 3, pp. 329-341, 2013.
122. D. M. Torres, C. D. Williams, and S. A. Harrison, "Features, diagnosis, and treatment of nonalcoholic fatty liver disease, " Clinical Gastroenterology and Hepatology, vol. 10, no. 8, pp. 837-858, 2012.
123. E. Boettcher, G. Csako, F. Pucino, R. Wesley, and R. Loomba, "Meta-Analysis: pioglitazone improves liver histology and fibrosis in patients with non-Alcoholic steatohepatitis, " Alimentary Pharmacology and Therapeutics, vol. 35, no. 1, pp. 66-75, 2012.
124. V. Ratziu, P. Giral, S. Jacqueminet, et al., "Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) trial, " Gastroenterology, vol. 135, no. 1, pp. 100-110, 2008.
125. V. Ratziu, F. Charlotte, C. Bernhardt, et al., "Long-Term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial, " Hepatology, vol. 51, no. 2, pp. 445-453, 2010.
126. D. M. Torres, F. J. Jones, J. C. Shaw, C. D. Williams, J. A. Ward, and S. A. Harrison, "Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial, " Hepatology, vol. 54, no. 5, pp. 1631-1639, 2011.
127. M. Gao, Y. Ma, M. Alsaggar, and D. Liu, "Dual outcomes of rosiglitazone treatment on fatty liver, " The AAPS Journal, vol. 18, no. 4, pp. 1023-1031, 2016.
128. P. Pettinelli and L. A. Videla, "Up-regulation of PPAR- mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction, " Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1424-1430, 2011.
129. M. Inoue, T. Ohtake, W. Motomura, et al., "Increased expression of PPAR in high fat diet-induced liver steatosis in mice, " Biochemical and Biophysical Research Communications, vol. 336, no. 1, pp. 215-222, 2005.
130. Y.-L. Zhang, A. Hernandez-Ono, P. Siri, et al., "Aberrant hepatic expression of PPAR2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis, " Journal of Biological Chemistry, vol. 281, no. 49, pp. 37603-37615, 2006.
131. A. Vidal-Puig, M. Jimenez-Li'nan, B. B. Lowell, et al., "Regulation of PPAR gene expression by nutrition and obesity in rodents, " The Journal of Clinical Investigation, vol. 97, no. 11, pp. 2553-2561, 1996.
132. G. P. Ables, "Update on Ppar and nonalcoholic fatty liver disease, " PPAR Research, vol. 2012, Article ID 912351, 5 pages, 2012.
133. J. Sakamoto, H. Kimura, S. Moriyama, et al., "Activation of human peroxisome proliferator-Activated receptor (PPAR) subtypes by pioglitazone, " Biochemical and Biophysical Research Communications, vol. 278, no. 3, pp. 704-711, 2000.
134. E. Xu, M.-P. Forest, M. Schwab, et al., "Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPAR, " Hepatology, vol. 59, no. 5, pp. 1803-1815, 2014.
135. C. W. Wu, E. S. H. Chu, C. N. Y. Lam, et al., "PPAR is essential for protection against nonalcoholic steatohepatitis, " GeneTherapy, vol. 17, no. 6, pp. 790-798, 2010.
136. E. Morán-Salvador, M. López-Parra, V. García-Alonso, et al., "Role for PPAR in obesity-induced hepatic steatosis as determined by hepatocyte- And macrophage-specific conditional knockouts, " FASEB Journal, vol. 25, no. 8, pp. 2538-2550, 2011.
137. S. Kuntz, S. Mazerbourg, M. Boisbrun, et al., "Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones, " Biochemical Pharmacology, vol. 92, no. 1, pp. 102-111, 2014.
138. A. Galli, T. Mello, E. Ceni, E. Surrenti, and C. Surrenti, "The potential of antidiabetic thiazolidinediones for anticancer therapy, " ExpertOpinion on InvestigationalDrugs, vol. 15, no. 9, pp. 1039-1049, 2006.
139. C.-W. Wu, G. C. Farrell, and J. Yu, "Functional role of peroxisome-proliferator-Activated receptor in hepatocellular carcinoma, " Journal of Gastroenterology and Hepatology, vol. 27, no. 11, pp. 1665-1669, 2012.
140. A. Laganà, S. Vitale, A. Nigro, et al., "Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives, " International Journal of Molecular Sciences, vol. 17, no. 7, p. 999, 2016.
141. J. Yu, B. Shen, E. S. H. Chu, et al., "Inhibitory role of peroxisome proliferator-Activated receptor gamma in hepatocarcinogenesis in mice and in vitro, " Hepatology, vol. 51, no. 6, pp. 2008-2019, 2010.
142. A. Galli, E. Ceni, T. Mello, et al., "Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-Transgenic mice by peroxisome proliferator-Activated receptor -independent regulation of nucleophosmin, " Hepatology, vol. 52, no. 2, pp. 493-505, 2010.
143. E. Ceni, T. Mello, M. Tarocchi, et al., "Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells, " World Journal of Gastroenterology, vol. 11, no. 8, pp. 1122-1130, 2005.
144. X. Ren, D. Zheng, F. Guo, et al., "PPAR suppressed Wnt/-catenin signaling pathway and its downstream effector SOX9 expression in gastric cancer cells, " Medical Oncology, vol. 32, no. 4, 2015.
145. K. Wu, Y. Yang, D. Liu, et al., "Activation of PPAR suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway, " Oncotarget, 2016.
146. S. Dionne, E. Levy, D. Levesque, and E. G. Seidman, "PPAR ligand 15-deoxy-delta 12, 14-prostaglandin J2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis, " Anticancer Research, vol. 30, no. 1, pp. 157-166, 2010.
147. O. Pellerito, A. Notaro, S. Sabella, et al., "WIN induces apoptotic cell death in human colon cancer cells through a block of autophagic flux dependent on PPAR down-regulation, " Apoptosis, vol. 19, no. 6, pp. 1029-1042, 2014.
148. D. M. Ray, S. H. Bernstein, and R. P. Phipps, "Humanmultiple myeloma cells express peroxisome proliferator-Activated receptor and undergo apoptosis upon exposure to PPAR ligands, " Clinical Immunology, vol. 113, no. 2, pp. 203-213, 2004.
149. A. Galli, E. Ceni, D. W. Crabb, et al., "Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR independent mechanisms, " Gut, vol. 53, no. 11, pp. 1688-1697, 2004.
150. L.-Q. Cao, Z.-L. Shao, H.-H. Liang, et al., "Activation of peroxisome proliferator-Activated receptor- (PPAR) inhibits hepatoma cell growth via downregulation of SEPT2 expression, " Cancer Letters, vol. 359, no. 1, pp. 127-135, 2015.
151. I. Cellai, G. Petrangolini, M. Tortoreto, et al., "In vivo effects of rosiglitazone in a human neuroblastoma xenograft, " British Journal of Cancer, vol. 102, no. 4, pp. 685-692, 2010.
152. B. Shen, E. S. H. Chu, G. Zhao, et al., "PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice, " British Journal of Cancer, vol. 106, no. 9, pp. 1486-1494, 2012.
153. P. Avena, W. Anselmo, D. Whitaker-Menezes, et al., "Compartment-specific activation of PPAR governs breast cancer tumor growth, via metabolic reprogramming and symbiosis, " Cell Cycle, vol. 12, no. 9, pp. 1360-1370, 2013.
154. J. A. Menendez, "Fine-Tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives, " Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1801, no. 3, pp. 381-391, 2010.
155. D. F. Calvisi, C. Wang, C. Ho, et al., "Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma, " Gastroenterology, vol. 140, no. 3, pp. 1071-1083, 2011.
156. J. Hu, L. Che, L. Li, et al., "Co-Activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice, " Scientific Reports, vol. 6, Article ID 20484, 2016.
157. L. Li, L. Che, K. M. Tharp, et al., "Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans, " Hepatology, vol. 63, no. 6, pp. 1900-1913, 2016.
158. L. Li, G. M. Pilo, X. Li, et al., "Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans, " Journal of Hepatology, vol. 64, no. 2, pp. 333-341, 2016.
159. D. Cao, X. Song, L. Che, et al., "Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells, " Liver International, 2016.
160. J. Samarin, V. Laketa, M. Malz, et al., "PI3K/AKT/mTORdependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells, " Hepatology, vol. 63, no. 3, pp. 813-826, 2016.
161. C. Wang, L. Che, J. Hu, et al., "Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade, " Liver International, vol. 36, no. 8, pp. 1176-1186, 2016.
162. M. Laplante and D. M. Sabatini, "Regulation ofmTORC1 and its impact on gene expression at a glance, " Journal of Cell Science, vol. 126, pp. 1713-1719, 2013.
163. G. Panasyuk, C. Espeillac, C. Chauvin, et al., "PPAR contributes to PKM2 and HK2 expression in fatty liver, " Nature Communications, vol. 3, article 672, 2012.
164. D. P. King and J. S. Takahashi, "Molecular genetics of circadian rhythms in mammals, " Annual Review of Neuroscience, vol. 23, pp. 713-742, 2000.
165. U. Schibler and P. Sassone-Corsi, "A web of circadian pacemakers, " Cell, vol. 111, no. 7, pp. 919-922, 2002.
166. D. Feng and M. A. Lazar, "Clocks, metabolism, and the epigenome, " Molecular Cell, vol. 47, no. 2, pp. 158-167, 2012.
167. N. Koike, S.-H. Yoo, H.-C. Huang, et al., "Transcriptional architecture and chromatin landscape of the core circadian clock in mammals, " Science, vol. 338, no. 6105, pp. 349-354, 2012.
168. J. Morf, G. Rey, K. Schneider, et al., "Cold-inducible RNAbinding protein modulates circadian gene expression posttranscriptionally, " Science, vol. 338, no. 6105, pp. 379-383, 2012.
169. G. Rey, F. Cesbron, J. Rougemont, H. Reinke, M. Brunner, and F. Naef, "Genome-wide and phase-specificDNA-binding rhythms of BMAL1 control circadian output functions in mouse liver, " PLoS Biology, vol. 9, no. 2, Article ID e1000595, 2011.
170. H. Yoshitane, H. Ozaki, H. Terajima, et al., "CLOCK-controlled polyphonic regulation of circadian rhythms through canonical and noncanonical E-boxes, "Molecular and Cellular Biology, vol. 34, no. 10, pp. 1776-1787, 2014.
171. Y. Tahara and S. Shibata, "Circadian rhythms of liver physiology and disease: experimental and clinical evidence, " Nature Reviews Gastroenterology and Hepatology, vol. 13, no. 4, pp. 217-226, 2016.
172. X. Tong and L. Yin, "Circadian rhythms in liver physiology and liver diseases, " Comprehensive Physiology, vol. 3, no. 2, pp. 917-940, 2013.
173. S. Sahar and P. Sassone-Corsi, "Metabolism and cancer: the circadian clock connection, " Nature Reviews Cancer, vol. 9, no. 12, pp. 886-896, 2009.
174. C. B. Peek, A. H. Affinati, K. M. Ramsey, et al., "Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice, " Science, vol. 342, no. 6158, Article ID1243417, 2013.
175. M. D. Hirschey, T. Shimazu, J.-Y. Huang, B. Schwer, and E. Verdin, "SIRT3 regulatesmitochondrial protein acetylation and intermediary metabolism, " Cold Spring Harbor Symposia on Quantitative Biology, vol. 76, pp. 267-277, 2011.
176. G. F. Gibbons, D. Patel, D. Wiggins, and B. L. Knight, "The functional efficiency of lipogenic and cholesterogenic gene expression in normal mice and in mice lacking the peroxisomal proliferator-Activated receptor-Alpha (PPAR-), " Advances in Enzyme Regulation, vol. 42, pp. 227-247, 2002.
177. D. D. Patel, B. L. Knight, D. Wiggins, S. M. Humphreys, and G. F. Gibbons, "Disturbances in the normal regulation of SREBP-sensitive genes in PPAR-deficient mice, " Journal of Lipid Research, vol. 42, no. 3, pp. 328-337, 2001.
178. K. Oishi, H. Shirai, and N. Ishida, "CLOCK is involved in the circadian transactivation of peroxisome-proliferator-Activated receptor - (PPAR-) in mice, " Biochemical Journal, vol. 386, no. 3, pp. 575-581, 2005.
179. P. Gervois, S. Chopin-Delannoy, A. Fadel, et al., "Fibrates increase human REV-ERB- expression in liver via a novel peroxisome proliferator-Activated receptor response element, " Molecular Endocrinology, vol. 13, no. 3, pp. 400-409, 1999.
180. L. Canaple, J. Rambaud, O. Dkhissi-Benyahya, et al., "Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-Activated receptor - defines a novel positive feedback loop in the rodent liver circadian clock, " Molecular Endocrinology, vol. 20, no. 8, pp. 1715-1727, 2006.
181. L. Chen and G. Yang, "PPARs integrate the mammalian clock and energy metabolism, " PPAR Research, vol. 2014, Article ID 653017, 6 pages, 2014.
182. F. Gachon, N. Leuenberger, T. Claudel, et al., "Proline- And acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-Activated receptor - (PPAR-) activity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4794-4799, 2011.
183. A. Benavides, M. Siches, and M. Llobera, "Circadian rhythms of lipoprotein lipase and hepatic lipase activities in intermediate metabolism of adult rat, " American Journal of Physiology- Regulatory Integrative and Comparative Physiology, vol. 275, no. 3, part 2, pp. R811-R817, 1998.
184. M. C. Hunt, P. J. G. Lindquist, J. M. Peters, F. J. Gonzalez, U. Diczfalusy, and S. E. H. Alexson, "Involvement of the peroxisome proliferator-Activated receptor - in regulating longchain acyl-CoA thioesterases, " Journal of Lipid Research, vol. 41, no. 5, pp. 814-823, 2000.
185. M. C. Hunt, K. Solaas, B. Frode Kase, and S. E. H. Alexson, "Characterization of an acyl-CoA thioesterase that functions as a major regulator of peroxisomal lipid metabolism, " Journal of Biological Chemistry, vol. 277, no. 2, pp. 1128-1138, 2002.
186. K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre, et al., "PPAR- And PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene, " The EMBO Journal, vol. 15, no. 19, pp. 5336-5348, 1996.
187. M. Kawai, C. B. Green, B. Lecka-Czernik, et al., "A circadianregulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR- nuclear translocation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 23, pp. 10508-10513, 2010.
188. G. Yang, Z. Jia, T. Aoyagi, D. McClain, R. M. Mortensen, and T. Yang, "Systemic ppar deletion impairs circadian rhythms of behavior and metabolism, " PLoS ONE, vol. 7, no. 8, Article ID e38117, 2012.
189. C. Liu, S. Li, T. Liu, J. Borjigin, and J. D. Lin, "Transcriptional coactivator PGC-1- integrates themammalian clock and energy metabolism, " Nature, vol. 447, no. 7143, pp. 477-481, 2007.
190. J. Sonoda, I. R. Mehl, L.-W. Chong, R. R. Nofsinger, and R. M. Evans, "PGC-1 controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 12, pp. 5223-5228, 2007.
191. H. R. Ueda, W. Chen, A. Adachi, et al., "A transcription factor response element for gene expression during circadian night, " Nature, vol. 418, no. 6897, pp. 534-539, 2002.
192. C. Esau, S. Davis, S. F. Murray, et al., "miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, " Cell Metabolism, vol. 3, no. 2, pp. 87-98, 2006.
193. D. Gatfield, G. Le Martelot, C. E. Vejnar, et al., "Integration of microRNA miR-122 in hepatic circadian gene expression, " Genes and Development, vol. 23, no. 11, pp. 1313-1326, 2009.
194. A. Neufeld-Cohen, M. S. Robles, R. Aviram, et al., "Circadian control of oscillations in mitochondrial rate-limiting enzymes and nutrient utilization by PERIODproteins, " Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 113, no. 12, pp. E1673-E1682, 2016.
195. E. Filipski, P. F. Innominato, M. W. Wu, et al., "Effects of light and food schedules on liver and tumor molecular clocks in mice, " Journal of the National Cancer Institute, vol. 97, no. 7, pp. 507-517, 2005.
196. E. Filipski, P. Subramanian, J. Carrière, C. Guettier, H. Barbason, and F. Lévi, "Circadian disruption accelerates liver carcinogenesis in mice, " Mutation Research-Genetic Toxicology and Environmental Mutagenesis, vol. 680, no. 1-2, pp. 95-105, 2009.
197. K. D. Bruce, D. Szczepankiewicz, K. K. Sihota, et al., "Altered cellular redox status, sirtuin abundance and clock gene expression in amouse model of developmentally primed NASH, " Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1861, no. 7, pp. 584-593, 2016.
198. U. S. Udoh, J. A. Valcin, K. L. Gamble, and S. M. Bailey, "The molecular circadian clock and alcohol-induced liver injury, " Biomolecules, vol. 5, no. 4, pp. 2504-2537, 2015.
199. K. Honma, M. Hikosaka, K. Mochizuki, and T. Goda, "Loss of circadian rhythm of circulating insulin concentration induced by high-fat diet intake is associated with disrupted rhythmic expression of circadian clock genes in the liver, " Metabolism, vol. 65, no. 4, pp. 482-491, 2016.
200. F. W. Turek, C. Joshu, A. Kohsaka, et al., "Obesity andmetabolic syndrome in circadianClockmutant mice, " Science, vol. 308, no. 5724, pp. 1043-1045, 2005.
201. K. L. Eckel-Mahan, V. R. Patel, S. de Mateo, et al., "Reprogramming of the circadian clock by nutritional challenge, " Cell, vol. 155, no. 7, pp. 1464-1478, 2013.
202. K. Matsusue, T. Kusakabe, T. Noguchi, et al., "Hepatic steatosis in leptin-deficient mice is promoted by the PPAR target gene Fsp27, " Cell Metabolism, vol. 7, no. 4, pp. 302-311, 2008.
203. C. B. Green, N. Douris, S. Kojima, et al., "Loss of Nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis and diet-induced obesity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9888-9893, 2007.
204. Y.-M. Lin, J. H. Chang, K.-T. Yeh, et al., "Disturbance of circadian gene expression in hepatocellular carcinoma, " Molecular Carcinogenesis, vol. 47, no. 12, pp. 925-933, 2008.
205. B. Zhao, J. Lu, J. Yin, et al., "A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma, " Liver International, vol. 32, no. 9, pp. 1451-1459, 2012.
206. S. Ishibashi, S. Yamashita, H. Arai, et al., "EffectsofK-877, anovel selective PPAR- modulator (SPPARM-), in dyslipidaemic patients: a randomized, double blind, active- And placebocontrolled, phase 2 trial, " Atherosclerosis, vol. 249, pp. 36-43, 2016.
207. S. Raza-Iqbal, T. Tanaka, M. Anai, et al., "Transcriptome analysis of K-877 (A novel selective PPAR- modulator (SPPARM-))-regulated genes in primary human hepatocytes and the mouse liver, " Journal of Atherosclerosis and Thrombosis, vol. 22, no. 8, pp. 754-772, 2015.
208. J. P. Taygerly, L. R. McGee, S. M. Rubenstein, et al., "Discovery of INT131: a selective PPAR modulator that enhances insulin sensitivity, " Bioorganic and Medicinal Chemistry, vol. 21, no. 4, pp. 979-992, 2013.
209. B. Cariou, R. Hanf, S. Lambert-Porcheron, et al., "Dual peroxisome proliferator-Activated receptor -/ agonist gft505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects, " Diabetes Care, vol. 36, no. 10, pp. 2923-2930, 2013.
210. B. Cariou, Y. Zäir, B. Staels, and E. Bruckert, "Effects of the new dual PPAR-/ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism, " Diabetes Care, vol. 34, no. 9, pp. 2008-2014, 2011.
211. B. Staels, A. Rubenstrunk, B. Noel, et al., "Hepatoprotective effects of the dual peroxisome proliferator-Activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, " Hepatology, vol. 58, no. 6, pp. 1941-1952, 2013.
212. V. Ratziu, S. A. Harrison, S. Francque, et al., "Elafibranor, an agonist of the peroxisome proliferator-Activated receptor-And -, induces resolution of nonalcoholic steatohepatitis without fibrosisworsening, " Gastroenterology, vol. 150, no. 5, pp. 1147.e5-1159.e5, 2016.